• 5분 읽기
• 2025년 10월 18일 게시
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
Let's be honest, the world has gone a bit mad for weight-loss drugs. You can't open a newspaper or scroll through social media without hearing about the latest 'miracle jab'. For the pharmaceutical giants behind them, it has been nothing short of a gold rush, with billions pouring in as waistlines shrink. But whenever a market gets this hot, you can be sure of one thing, a politician will eventually show up to throw a spanner in the works. And right on cue, former President Trump has pledged to take aim at their sky-high prices.
To me, this is where things get properly interesting for investors. When the golden goose gets a fright, the whole farmyard is thrown into disarray.
The current market leaders have had a spectacular run. They created a product that everyone, it seems, wants. The profits have been astronomical, and their share prices have reflected that. But the prospect of government-enforced price negotiations changes the entire equation. Suddenly, those beautiful, wide profit margins look a lot less certain.
I’ve seen this play out before. Political pressure on a lucrative industry creates a ripple effect. The big, established players, once seen as invincible, suddenly have to look over their shoulders. Their business model, built on premium pricing, could face a fundamental threat. This isn't just idle chatter, it's a potential earthquake for the sector, and the first tremors are already being felt in the market. The question is, who stands to benefit from the aftershocks?
This is where the opportunity lies, in my view. When the market leaders are forced onto the defensive, it creates an opening for the smaller, more innovative upstarts. A whole host of biotech firms have been beavering away in their labs, developing the next generation of obesity treatments. They might have different mechanisms, better side-effect profiles, or, crucially, more convenient delivery methods. Think a simple pill instead of a weekly injection.
This is a classic case of disruption, a theme we've explored in our Weight-Loss Drug Shakeup: What's Next for Biotechs? basket, where political winds could fill the sails of smaller, more nimble companies. Firms like ORAMED PHARMACEUTICALS, working on oral delivery, or BIOMEA FUSION, with its novel approaches, could suddenly find themselves in a very favourable position. If the current blockbusters become less profitable or accessible due to price controls, doctors and patients will naturally start looking for alternatives.
Of course, you shouldn't invest based on a politician's promise alone. The real story here is the underlying innovation. The current crop of drugs are impressive, but they are not the final word on obesity treatment. The biotech sector is brimming with companies trying to build a better mousetrap. They are exploring everything from treatments for rare genetic disorders of obesity, like Rhythm Pharmaceuticals, to therapies that offer a completely different way of tackling metabolic health.
The political pressure simply acts as a potential catalyst. It could accelerate the shift towards these newer, potentially superior, alternatives. Healthcare systems are groaning under the cost of obesity, and if a cheaper, effective option comes along whilst the market leader is tangled in pricing battles, its path to adoption could be much quicker. This combination of genuine scientific progress and a shifting market landscape is what makes this a compelling, if speculative, thesis. Investing here is a bet that the future of weight-loss treatment will be more diverse than it is today.
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
전체 바스켓 보기:Weight-Loss Drug Shakeup: What's Next for Biotechs?
2026년 9월 22일 게시
기사 읽기
2026년 9월 22일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기
2026년 9월 22일 게시
기사 읽기
2026년 9월 22일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 20일 게시
기사 읽기
2026년 9월 19일 게시
기사 읽기